Zenocutuzumab
Merusā Zeno Shows Higher Response Rates in NRG1+ Pancreatic and Lung Cancers (ESMO 2023)
Anika Sharma
ESMO 2023: 1618P Currently, Ipsen’s Onivyde is the standard of care, but it offers only a 7% chance of response ...
Zenocutuzumab receives Breakthrough Designation from the FDA for NRG1+ Pancreatic Cancer
SG Tylor
Source – Merus On July 5, The FDA has granted breakthrough therapy designation to zenocutuzumab (MCLA-128) as a treatment for ...
